Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus

Barkai, László József; Sipter, Emese; Csuka, Dorottya; Prohászka, Zoltán; Pilely, Katrine; Garred, Peter; Hosszúfalusi, Nóra

Published in:
Frontiers in Immunology

DOI:
10.3389/fimmu.2019.00509

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Barkai, L. J., Sipter, E., Csuka, D., Prohászka, Z., Pilely, K., Garred, P., & Hosszúfalusi, N. (2019). Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus. Frontiers in Immunology, 10, [509]. https://doi.org/10.3389/fimmu.2019.00509

Download date: 05. May. 2020
Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus

László József Barkai, Emese Sipter, Dorottya Csuka, Zoltán Prohászka, Katrine Pilely, Peter Garred and Nóra Hosszúfalusi

3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Bacterial infections are frequent and severe in patients with diabetes mellitus. Whether diabetes per se induces functional alterations in the complement system hampering activation during infection is unknown. We investigated key elements of the complement system during bacterial infections in patients with type 2 diabetes mellitus (T2DM) and compared them to non-diabetic (ND) individuals. Using a prospective design, we included 197 T2DM, and 196 ND subjects, all with clinical diagnosis of acute community-acquired bacterial infections. Functional activities of the ficolin-3-mediated lectin (F3-LP), mannose binding lectin-mediated lectin- (MBL-LP), classical (CP), and alternative pathways (AP), as well as concentrations of complement activation products C4d and sC5b-9 were determined. Functional in vitro activities of F3-LP and AP were significantly higher in T2DM than in ND subjects, (median 64% vs. 45%, p = 0.0354 and 75 vs. 28%, p = 0.0013, respectively), indicating a decreased in vivo activation and lack of consumption of F3-LP and AP in T2DM patients, whereas no difference in functional capacities of CP and MBL-LP were observed between T2DM and ND subjects. Diminished F3-LP and AP activation was most pronounced in diabetic patients with urinary tract infections with positive microbiological culture results for Escherichia coli bacteria. In the T2DM group 3-months mortality significantly associated with diminished F3-LP and AP, but not with CP activation. Concentrations of C4d and sC5b-9 were significantly lower in the T2DM than in ND patients. In conclusion, we found impaired F3-LP activation and lack of AP amplification during bacterial infections in patients with type 2 diabetes, compared to non-diabetic subjects, suggesting a diminished complement mediated protection to bacterial infections in T2DM.

Keywords: ficolin-3, lectin pathway, alternative pathway, classical pathway, complement, type 2 diabetes, bacterial infection, Escherichia coli
INTRODUCTION

Diabetes is considered as an independent risk factor for community acquired and nosocomial infections (1). It increases the susceptibility to infectious diseases, moreover, prolongs the infection-related hospitalization and may enhance its mortality (2, 3). The background of this acquired immunodeficiency is not completely clear (4, 5). Regarding innate immunity, in vitro studies identified polymorphonuclear neutrophil (PMN) dysfunction including impaired PMN transmigration through barriers (6), reduced PMN chemotaxis (7) and as the most convincing evidence, decreased microbial killing (7–9). Available data are controversial for the adaptive immunity. T-lymphocyte dysfunction seems to be dependent on glycemic control, as T cell proliferation was impaired in poorly controlled patients with type 1 diabetes (10). By contrast, patients with relatively good metabolic control showed a robust secondary immune response to standard antigens (11). With regard to humoral immunity, glycation may impair the biological function of antibodies (12).

Only a few data are known about the activation of the complement system in bacterial infections in diabetes. Nevertheless, complement activation has been shown to be a contributing factor to complications of diabetes (13). C3 as a central component of complement and its activation may contribute to diabetic nephropathy, retinopathy and neuropathy (13–17). Regarding the macrovascular complications, Hess and colleagues showed the possible role of C3 in diabetes related cardiovascular risk, by proposing a mechanism in which C3 participates in a hypofibrinolytic, and thus prothrombotic state (18). In a recent review, Ghosh and colleagues summarized the body of evidence supporting the role of the complement system and complement regulatory proteins in the pathogenesis of diabetic vascular complications, with specific emphasis on the role of the membrane attack complex (MAC) and of CD59, an extracellular cell membrane-anchored inhibitor of MAC formation that is inactivated by non-enzymatic glycation (19).

On the other hand a diminished complement-activating capacity through the classical pathway in type 2 diabetes mellitus was reported in the context of free sialic acid as a potential modulator of complement activation (20). Regarding the effect of high glucose on complement activation, in vitro assays showed that classical and alternative pathway activities were not affected by elevated glucose or other hexoses tested (21). However, high glucose concentrations inhibited the complement activation via the mannose binding lectin (MBL) mediated pathway (21). The role of the complement system in infectious diabetic complications has been studied scarcely.

Ficolins–1,–2,–3 and mannose binding lectin are pattern recognition molecules playing an important role in activating the lectin complement pathway (22–24). MBL binds directly to high mannosse or fucose structures on microbial surfaces and drives activation of the lectin pathway (25). Ficolin-1 and ficolin-3 were shown to bind carbohydrate structures of bacteria, especially N-acetyl-galactosamine, and N-acetyl-D-glucosamine, additionally ficolin-3 can associate also with glucose and fucose (26). Ficolin-2 is the major 1,3-β-glucan-binding protein in human plasma and can bind to lipoteichoic acid, thus, ficolin-2 may bind to a wide variety of fungi and Gram-positive bacteria (27, 28). Two patients with congenital ficolin-3 deficiency were reported suffering from serious and life-threatening infections caused by Haemophilus influenzae and Pseudomonas aeruginosa (29), and necrotizing colitis (30). Despite these data, previously, ficolin-3 was identified to bind only a few common pathogenic bacteria (31). Moreover, its potential to activate the lectin pathway in vivo, and to augment phagocytosis, has been described only for the opportunistic bacteria, Hafnia alvei (32) until now. The role of ficolins in infections of patients with diabetes was not studied earlier, despite that MBL, and ficolins recognize specific carbohydrate patterns expressed by microorganisms, and elevated blood glucose and/or protein glycation seen in diabetes may alter such carbohydrate patterns.

Therefore, the aim of our study was to investigate complement activation and consumption via the alternative, classical and lectin pathways during bacterial infections in patients with type 2 diabetes (T2DM). Accordingly, the objective of our study was to provide complex observational data on the lectin pathway focusing on the ficolin-3-mediated pathway in diabetes mellitus in the context of community acquired bacterial infections.

MATERIALS AND METHODS

Patients

In this prospective, observational study patients with clinical diagnosis of bacterial infections were enrolled and divided into two groups according to the presence [T2DM group, based on WHO criteria (33) or absence of type 2 diabetes mellitus (non-diabetic, ND group)]. Inclusion criteria were a minimum age of 18 years and the need for hospitalization on a general medicine ward due to acute community-acquired bacterial infection. Patients with hematological, oncological or immunological illnesses were excluded. Sepsis was defined in case of at least two existing SIRS (systemic inflammatory response syndrome) criteria from the following: 1. Temperature >38°C (100.4°F) or <36°C (96.8°F), 2. Heart rate >90/min, 3. Respiratory rate >20/min or PaCO2 <32 mm Hg, 4. WBC >12.000/mm³, <4.000/mm³, or >10% bands (34, 35). To ascertain post infection mortality rates, subjects were followed-up after a 3-months period through their social insurance identification number, and via interview on their-, or their family member’s telephone number.

Data Collection

Clinical data of current symptoms and past medical history were assembled from the patients’ medical records and a further thorough interview after admission to the hospital.

Blood Sampling

Samples (serum, EDTA-anticoagulated plasma and sodium-citrate-anticoagulated plasma) of both groups were collected from antecubital venipuncture within the first 3 days of the hospitalization, between September 2013 and December 2016. Cells and supernatants were separated by centrifugation at 2000x
g and the aliquoted serum and plasma samples were stored at −70°C until analysis.

**Determination of Complement Parameters**

For functional assessment of either the alternative pathway (AP, reference range based on the values of healthy blood donors: 70–125%), or the MBL-mediated lectin pathway activation (MBL-LP, measured by MBL activation with mannan, reference range: 30–130%), as well as the ficolin-3-mediated lectin pathway activation (F3-LP, measured by ficolin-3 activation with acetylated BSA, reference range: 25–130%) in serum samples, commercial ELISA kits (Wieslab, Eurodiagnostica, Malmö, Sweden) detecting generation of terminal complement complex (C9 neo-epitope) were used, according to the manufacturer’s instructions. Total classical pathway activity (CP, reference range: CH50 48–103 U/mL) was assessed with a home-made sheep-erythrocyte hemolytic titration test, using serum samples. In these standardized assays, the decreased or absent in vitro functional activity of complement pathways may be related to in vivo consumption (36). The concentrations of ficolin-1 (F1, reference range: 10–1,890 ng/mL) (37), ficolin-2 (F2, reference range: 100–1220 µg/mL) (38), ficolin-3 (F3, reference range, 3–54 µg/mL) (39) and MBF (reference range: 0–5,000 ng/mL) (40) were determined in serum by standard sandwich ELISA techniques: monoclonal antibodies specific for each protein were coated on the plates, and after the incubation of the samples, biotinylated antibodies were applied, and streptavidin/HRP coated on the plates, and after the incubation of the samples, immunodiffusion was performed to measure the antigenic concentration of C1-inhibitor (reference range: 0.15–0.30 g/L) by turbidimetry (Beckman Coulter, Brea, CA), whereas, radi al functional activity of complement pathways may be related to in vivo consumption (36). The concentrations of ficolin-1 (F1, reference range: 10–1,890 ng/mL) (37), ficolin-2 (F2, reference range: 100–1220 µg/mL) (38), ficolin-3 (F3, reference range, 3–54 µg/mL) (39) and MBF (reference range: 0–5,000 ng/mL) (40) were determined in serum by standard sandwich ELISA techniques: monoclonal antibodies specific for each protein were coated on the plates, and after the incubation of the samples, biotinylated antibodies were applied, and streptavidin/HRP complexes were used for detection.

Complement C3 (reference range: 0.90–1.80 g/L) and C4 (reference range: 0.15–0.55 g/L) levels were measured in serum by turbidimetry (Beckman Coulter, Brea, CA), whereas, radial immunodiffusion was performed to measure the antigenic concentration of C1-inhibitor (reference range: 0.15–0.30 g/L) using polyclonal goat anti-human C1-inhibitor (Quidel, San Diego, CA, USA). Commercial ELISA kits were used to quantify the levels of C4d (reference range: 0.70–6.30 µg/mL) and sC5b-9, the soluble form of the terminal pathway activation complex (reference range: 110–252 ng/mL); both complement activation products were measured in EDTA-plasma (Quidel, San Diego, CA, USA).

**Other Laboratory Measurements**

C-reactive protein (hsCRP) levels were ascertained by turbidimetry (Beckman Coulter, Brea, CA), other clinical laboratory parameters were measured with Beckman Coulter (Brea, CA) or the Cell-Dyn 3,500 hematology analyzer. Blood glucose level was determined using the hexokinase assay. Fructosamine was measured with Roche Fructosamine colorimetric test kit (using nitrotetrazolium blue chloride on a Beckman Analyzer AU680, reference range: 205–280 µmol/L). HbA1c concentration was quantified with ion exchange high pressure liquid chromatography (HPLC) method (reference range: 4.0–6.0%). Advanced glycation end product (AGE) levels of both groups were measured in skin by non-invasive autofluorescence technique (AGE Reader mu, DiagnOptics); according to the manufacturer’s instructions (41).

**RESULTS**

**Clinical Characteristics of the Two Cohorts**

A total of 197 T2DM and 196 ND subjects were included; clinical characteristics of the two groups are presented in Table 1. Blood glucose, glycation parameters reflecting short-, middle-, and long-term blood glucose levels (fructosamine, HbA1c, AGEs) and BMI were significantly higher (all p < 0.001) in the T2DM group compared to the ND. No differences were found between the two groups regarding age and gender distribution. Infection-related laboratory markers (C-reactive protein, white blood...
Complement Parameters in the Study Groups

In order to get a reasonably detailed profile on the complement system, concentrations of recognition molecules (ficolin-1, −2, −3, and MBL), levels of C1-inhibitor, C3, C4, C4d, sC5b-9, as well as functional activity of the ficolin-3- or MBL-mediated lectin pathway activation (referred to as F3-LP, or MBL-LP, respectively), and of the classical (CP) and alternative (AP) pathways were determined. As shown in Table 2 patients with bacterial infections but without diabetes (ND) had marked, strong complement activation, as reflected by the very high terminal pathway activation marker sC5b-9 levels. Patients with type 2 diabetes (T2DM) during infection had also elevated but significantly lower sC5b-9 concentrations when compared to ND ($p = 0.0022$). Regarding the complement activity of various complement pathways, diabetic patients and the ND group had similar classical pathway consumption (Table 2). In contrast, in vitro activation of F3-LP and AP were more pronounced in samples of patients with bacterial infections and diabetes in comparison with ND group, as reflected by the difference of F3-LP and AP activity (in average by 19−47% higher values observed by the in vitro activation test in T2DM, $p = 0.0354$, $p = 0.0013$, respectively) (Table 2). Note, that the higher in vitro complement pathway activation reflects a lower in vivo activation and/or consumption. The diminished in vivo activation of F3-LP and AP in diabetic patients with bacterial infections was not due to lower levels of ficolins or C4 as antigenic concentrations of these recognition molecules and complement components were similar in the two groups (Table 2). Concentrations of C3 were only slightly elevated in the T2DM group ($p = 0.0482$) (Table 2). No difference concerning MBL concentration and functional capacity of MBL-LP was observed between the two groups (Table 2). Importantly, diminished activation of F3-LP in patients with bacterial infections and diabetes was also supported by the significantly lower C4d concentrations, when compared to ND ($p = 0.0063$). Similarly, the significantly higher concentration of C1-inhibitor in the T2DM group compared to ND ($p < 0.0001$) may reflect the impaired activation and consumption of F3-LP (Table 2).

To further explore the relationship between consumption of different pathways during bacterial infections in diabetic patients and non-diabetic individuals, analyses of parallel consumptions were done. Consumption of various complement pathways such as CP, AP and F3-LP were defined according to the lower limit of the reference range, as indicated in Table 2 ($<48 \text{ U/mL}$, $<70\%$, $<25\%$, respectively). "No consumption" was considered if the values were equal or above the lower limit of the reference. As shown on Figure 1, distribution of complement consumption was polarized in non-diabetic patients: a significant percentage of ND patients fell into subgroups without any consumption (38% for CP and AP, 41% for F3-LP and AP) however, another significant percentage showed a consumption of both pathways (45% for CP and AP, 44% for F3-LP and AP) (Figures 1A,B). In contrast, diabetic patients with bacterial infections showed different patterns: 42% fell into subgroups of both pathways (45% for CP and AP, 44% for F3-LP and AP) while only 28% had a consumption of both pathways for CP and AP and 21% for F3-LP and AP. The T2DM group had less frequent parallel consumptions of F3-LP and AP in comparison with the ND group ($p = 0.0007$) (Figure 1B), and a similar finding was observed for CP and AP ($p = 0.0079$) (Figure 1A). In addition, when analyzing all three pathways together, 48% of ND patients, but only 27% of diabetic patients had parallel activation and consumption of all three pathways F3-LP, CP and AP ($p = 0.037$) (Figure 1C). This difference is mainly attributable to the diminished activation of F3-LP and AP in diabetes (Figure 1).

### Table 2: Complement results of the T2DM and ND groups.

| Complement parameters (reference range) | T2DM $n = 197$ | ND $n = 196$ | Significance |
|-----------------------------------------|---------------|--------------|--------------|
| **Ficolin-3-mediated lectin pathway (F3-LP)** | 64 (25–111) | 45 (16–92) | $p = 0.0354$ |
| **F3 conc. - µg/mL** | 36 (3–54) | 34 (22–62) | NS |
| **F1 conc. - ng/mL** | 558 (10–1900) | 568 (327–943) | NS |
| **F2 conc. - µg/mL** | 1.60 (1.00–12.20) | 1.50 (0.94–2.40) | NS |
| **MBL-mediated lectin pathway (MBL-LP) – % (30–130%)** | 73 (5–116) | 50 (5–111) | NS |
| **MBL conc. - ng/mL** | 982 (0–5000) | 888 (285–1963) | NS |
| **Alternative pathway (AP) - % (70–125%)** | 75 (18–98) | 28 (0–92) | $p = 0.0013$ |
| **Classical pathway (CP) - CH50 / U/mL** | 30.00 (13–63) | 30.00 (13–60) | NS |
| **C1-inhibitor - g/L** | 0.30 (0.15–0.30) | 0.27 (0.22–0.31) | $p < 0.0001$ |
| **C3 conc. - g/L** | 1.87 (0.90–1.80) | 1.76 (1.46–2.17) | $p = 0.0482$ |
| **C4 conc. - g/L** | 0.43 (0.15–0.55) | 0.42 (0.33–0.53) | NS |
| **C4d conc. - µg/mL** | 6.51 (0.70–6.30) | 7.87 (5.5–11.61) | $p = 0.0063$ |
| **sC5b-9 conc. - ng/mL** | 457 (110–252) | 516 (341–643) | $p = 0.0022$ |

Values indicate medians [25–75% percentile] of the variables; conc.: concentration. Mann-Whitney test was performed to compare study groups. The values in bold indicate the medians and the significant differences.
anatomic location of infections: respiratory tract (Resp.), urinary tract (UTI), skin and soft tissue (SSTI), and infections in other locations.

The diminished in vivo activation (lack of consumption) of F3-LP and AP among diabetic patients was most pronounced in case of UTI (Tables 3, 4). Non-diabetic subjects had in average 30% lower in vitro functional activity of F3-LP than patients with diabetes (37% [8–79] vs. 67% [21–102], p = 0.0456). Slight difference alike was observed in patients with sepsis and UTI (27% [6–73] vs. 67% [20–102], p = 0.038, Table 3). Note, that the observed lower in vitro complement pathway activity reflects a higher in vivo activation and/or consumption, and the higher in vitro complement pathway activation means a lower in vivo activation and/or consumption, as previously described. Similar results were seen in the subgroups with respiratory infection, though the difference between the groups did not reach statistical significance (Table 3). Regarding SSTIs, SSTIs with sepsis, and other localization of infections, no significant differences in F3-LP activity were seen between the groups (Table 3). Similarly, to the F3-LP, in vivo activation of AP was diminished among diabetic patients having respiratory or urinary tract infections (p = 0.0276 and p = 0.0092, respectively, Table 4). These two locations represented the majority of patients in both study groups.

Based on the pronounced difference in F3-LP and AP activity, we aimed to further analyze the subgroup with UTI. As shown on Figure 2, diabetic patients with positive culture results for Escherichia coli (E. coli) had diminished F3-LP activation when compared to those of non-diabetic subjects (70% [30–103] vs. 33% [16–91], p = 0.0286). Similar results were observed regarding AP (87% [77–99] vs. 6% [0–53], p = 0.0003). However, no difference concerning F3-LP and AP was observed for those, with non-E. coli UTIs. (Figure 2).

Association of Complement Activation and Consumption With Clinical Parameters

To determine the relationship of complement activation and consumption with clinical parameters including glycation-related markers in T2DM, Spearman correlation analysis was done. No associations of F3-LP or AP with blood glucose, fructosamine, or HbA1c were found, however, an inverse weak correlation of F3-LP with the long-term glycation marker of AGEs (p < 0.05, r = −0.2765) was observed among T2DM subjects.
Three-months mortality after bacterial infection was similar in the diabetic and non-diabetic groups (Table 1), however, lack of F3-LP activation and consumption with lack of AP amplification were associated with mortality in the diabetic group (p = 0.012 and p = 0.025, respectively) (Figure 3). Whereas, activation of CP, F3-LP and AP was present in 77, 62, and 76% of ND subjects who died, respectively, the same was not observed for T2DM patients. Although 60% of those diabetic patients who died had CP activation and consumption, this proportion was only 29 and 25% for F3-LP and AP, respectively (Figure 3). There was no difference in the occurrence of complement consumption among the groups with sepsis only (Figure 3).

**DISCUSSION**

In our prospective study, we found decreased in vivo activation of ficolin-3-mediated lectin and alternative pathways during bacterial infections in patients with type 2 diabetes in comparison with non-diabetic subjects. On the other hand, there was no difference between the two study groups regarding the classical pathway and the MBL-mediated lectin pathway activities. The functional assays we used in case of F3-LP, MBL-LP, CP, and AP detect the residual, inducible terminal complement complex generation in the given sample, as these tests are based on the in vitro activation of the samples using the specific activators of the F3-LP (acetylated bovine serum albumin), the MBL-LP (mannan), the CP (immune complexes) or the AP (lipopolysaccharide). Therefore, the observed higher in vitro activation capacity for F3-LP and AP activity found in the T2DM cohort indicate that these complement pathways have not been activated extensively in vivo. In accordance with the diminished in vivo activation in the T2DM patients, less increased sC5b-9 activation product concentrations were found in T2DM in comparison with the ND group. In addition, the observed higher C1-inhibitor concentrations along with the decreased C4d levels support a diminished in vivo F3-LP activation.

When we analyzed the F3-LP, AP, and CP pathways together, only 27% of diabetic patients had parallel activation in contrast to 48% of ND cases. This difference was mainly attributable to the diminished activation of F3-LP and AP in T2DM. However, one limitation of our study is that we do not have “baseline” (non-infectious) data regarding complement profile of the study subjects.

Regarding the different infection localizations, impaired F3-LP and AP activations were found in T2DM with urinary tract infections in comparison with the ND group. In diabetic patients having respiratory tract infections diminished activation of AP was seen, with a similar tendency regarding F3-LP activity. However, no changes were found in case of skin or soft tissue, or other types of infection locations between the two groups. Whether the observed difference in the altered activation of F3-LP and AP among the different localizations is explained by the different body compartments and/or the diversity of the etiological bacterial agents, still remains to be determined.

Recently, growing number of data have been published about the complement system and diabetes mellitus however, most of these studies have targeted chronic diabetes complications. Based on these observations activation of the complement system plays a role in diabetic vascular complications. C3 as a central component of complement system and its activation may contribute to chronic diabetic micro- and macrovascular complications (14–18). In a recent review, Ghosh and colleagues showed that increased complement activation may have an impact on the pathogenesis of diabetic vascular complications.

---

**TABLE 3 | Activity of ficolin-3-mediated lectin pathway (F3-LP) in relation to anatomic location of bacterial infections.**

| Infection type | T2DM n = 197 | ND n = 196 | Significance |
|---------------|-------------|------------|-------------|
| Respiratory   | 67          | 44         | NS          |
| n = 46        | [23–132]    | [15–89]    |             |
| Sepsis        | 52          | 39         | NS          |
| n = 31        | [12–103]    | [9–74]     |             |
| UTI           | 67          | 37         | p = 0.0456  |
| n = 60        | [20–102]    | [8–79]     |             |
| Sepsis        | 67          | 27         | p = 0.038   |
| n = 40        | [20–102]    | [6–73]     |             |
| SSTI          | 53          | 68         | NS          |
| n = 75        | [25–100]    | [18–114]   |             |
| Sepsis        | 53          | 72         | NS          |
| n = 31        | [30–85]     | [10–123]   |             |
| Other         | 59          | 63         | NS          |
| n = 16        | [21–136]    | [21–117]   |             |

*UTI, Urinary tract; SSTI, Skin and soft tissue infections. Due to low case number, sepsis subgroups for “Other” infections are not presented.

**TABLE 4 | Activity of alternative pathway (AP) in relation to anatomic location of bacterial infections.**

| Infection type | T2DM n = 197 | ND n = 196 | Significance |
|---------------|-------------|------------|-------------|
| Respiratory   | 77          | 17         | p = 0.0276  |
| n = 46        | [1–103]     | [0–71]     |             |
| Sepsis        | 68          | 6          | NS          |
| n = 31        | [0–101]     | [0–72]     |             |
| UTI           | 73          | 22         | p = 0.0092  |
| n = 60        | [18–98]     | [0–83]     |             |
| Sepsis        | 67          | 17         | NS          |
| n = 40        | [8–96]      | [0–91]     |             |
| SSTI          | 77          | 82         | NS          |
| n = 75        | [18–89]     | [0–102]    |             |
| Sepsis        | 48          | 6          | NS          |
| n = 31        | [6–81]      | [0–102]    |             |
| Other         | 68          | 32         | NS          |
| n = 16        | [27–110]    | [0–106]    |             |

*UTI, Urinary tract; SSTI, Skin and soft tissue infections. Due to low case number, sepsis subgroups for “Other” infections are not presented.

"n" indicates number of subjects. Values indicate medians [25–75% percentile] of AP (%). Mann-Whitney test was performed to compare study groups.

The values in bold indicate the medians and the significant differences.
FIGURE 2 | F3-LP and AP activity in subjects with UTI and a positive microbiological culture. Ficolin-3-mediated lectin (A) and alternative (B) pathway activations (in vitro) of patients with UTIs and positive urine and/or blood cultures were chosen from both cohorts. Depending on the presence or absence of the E. coli bacterium they were each once more divided into two subgroups. T2DM subjects with E. coli positive cultures had higher in vitro F3-LP levels than those of the ND cohort (70% [30–103] vs. 33% [16–91], p = 0.0286). Similar results were found regarding AP (87% [77–99] vs. 6% [0–53], p = 0.0003). Difference between the groups was analyzed with the Mann-Whitney test, *p < 0.05, and ***p < 0.001. Horizontal dashed lines indicate limits of reference ranges, horizontal red lines indicate median values of the variables.

FIGURE 3 | Occurrence of complement consumption in patients with bacterial infections, with (T2DM) or without (ND) diabetes mellitus. Bars indicate percentages of patients with consumption of classical (left), ficolin-3-mediated lectin (middle), or alternative (right) pathways, according to subgroups with or without sepsis and mortality within 3 months. The group ‘exit’ includes all patients who died, irrespective of the presence of sepsis. Left panel: p = 0.278, middle: p = 0.012, right: p = 0.025, chi-square test.

Remarkably, higher sC5b-9 values and renal deposition in patients with diabetes were observed and were shown to be related with diabetic nephropathy (42). On the other hand, diminished complement-activating capacity through the classical pathway in type 2 diabetes mellitus was reported in the context of free sialic acid as a potential modulator of complement activation (20). It has to be noted, that in these studies subjects were involved in an infection-free period. Limited data were reported about the complement system during infections in hyperglycemic conditions: a previous study demonstrated that sera taken from healthy donors in hyperglycemic conditions in vitro (glucose concentration: 10–17 mmol/L) altered the interaction of C3 and the pathogenic bacteria Staphylococcus aureus (43). To the best of our knowledge our prospective study is the first publication about a complex investigation of complement activation during bacterial infections in diabetes compared to non-diabetic status. Based on our detailed measurements, diminished activation of F3-LP and AP in diabetic patients with bacterial infections was not due to lower levels of ficolins, C4 or C3, as antigenic concentrations of these complement components were similar in the two groups, or even higher in case of C3 in the T2DM group, in accordance with previous data (42, 44). Average concentrations of components of the lectin pathway (LP) were described previously (45–47) and several studies reported their levels during ongoing infections, but not in T2DM (48–50). Furthermore, it has to be highlighted, that concentrations of these components may vary age-dependently (47), and different comorbidities may have influence on them (51, 52), therefore, it remains a subject of research, how different pathogens or severity of infections could affect their levels.
High glucose related alterations in glycation pattern of complement components, or changes in tertiary structure of complement components may represent a potential explanation for the diminished F3-LP activation and AP amplification during infections of diabetic patients. C3 mediated effector functions were found to be inhibited in hyperglycemic conditions and the elegant study of Hair et al. showed that the inhibition is related to glucose induced changes in the tertiary structure of C3 (43). In our study blood glucose levels, short- (fructosamine), middle- (HbA1c) or long- (AGE) term glycation markers per se were elevated in the T2DM group compared to ND group. However, none of them were associated with activation and consumption of F3-LP and AP, except an inverse correlation of the F3-LP activity with the long-term glycation marker of AGEs in diabetic subjects. One possible explanation for the missing association with the short- and middle-term glycemic parameters could be that despite their higher levels in the T2DM group, our diabetic patients had a relatively good glycemic control around the time of the infection, as shown by the acceptable levels of blood glucose, fructosamine, and HbA1c.

We also evaluated associations of complement activation with clinical parameters and observed that 3-months post infection mortalities were similar in both groups. However, lack of ficolin-3-mediated lectin pathway activation along with lack of alternative pathway amplification were associated with mortality only in the T2DM group. There was no difference in the occurrence of complement consumption among the groups with sepsis without fatal outcome.

Throughout the various types of bacterial infections, the most remarkable difference between the two groups, regarding F3-LP and AP activation, was found in patients with UTI, especially in those suffering from E. coli infection. Ficolin-3 is one of the most effective activator of the LP in vitro (53) although our knowledge of ficolin-3 interaction with human pathogens is limited. Based on previous studies some human pathogens, such as Hafnia alvei (32) can activate the ficolin-3 mediated lectin pathway and ficolin-3 is linked with growth inhibition of Aerococcus viridans (54). Additionally, ficolin-3 recognized pathogenic Pasteurella pneumotropica and two pathogenic E. coli (enteroaggregative E. coli O71 and enteropathogenic E. coli O111 ab:H2) in an interaction study (31), but Sorensen et al. did not find any binding capacity of four prototypic enteroaggregative E. coli strains to recombinant ficolin-3 (55). Complement evasion strategies of E. coli, and altered factor H could also contribute to the diminished F3-LP activation and AP amplification in T2DM patients having E. coli related UTIs.

CONCLUSIONS

In summary, we found impaired ficolin-3-mediated lectin pathway activation and decreased alternative pathway amplification during bacterial infections in patients with T2DM in comparison with non-diabetic individuals. Lack of ficolin-3-mediated lectin pathway and alternative pathway consumption in the T2DM group were associated with 3-months mortality. Less diabetic patients had parallel consumption of F3-LP, CP and AP compared to the non-diabetic subjects. Our data suggest that ficolin-3-mediated lectin and alternative pathway activations may have an impact on the clinical outcome of patients with type 2 diabetes having bacterial infections.

DATA AVAILABILITY

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

Study protocol was approved by the Hungarian Medical Research Council (TUKB 396/2013 - 31584/2013/EKU) and the Institutional Review Board of the Semmelweis University, Budapest. Patients were involved into the study after informed, written consent in accordance with the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

ZP, ES, and NH designed and supervised the study. LB, ES, NH, and DC collected the blood samples. LB, KP, and DC performed ELISA, functional and hemolysis assays. LB, ES, and NH collected clinical and laboratory data. LB and ZP performed the statistical analysis. LB, ES, NH, ZP and DC wrote the manuscript with the help of KP and PG, who revised it critically for important intellectual content. All authors revised and approved the manuscript.

FUNDING

This study was funded by EFSD New Horizons Program, Dr. Koranyi Andras Foundation, The Svend Andersen Research Foundation, The Danish Research Foundation of Independent Research (DFF-6110-00489), The Danish Heart Foundation (16-R107-A6650-22966), and the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic programme of the Semmelweis University.

ACKNOWLEDGMENTS

The authors wish to express their gratitude toward Mr. Jesper Andresen for excellent technical assistance.

REFERENCES

1. Muller LM, Gorter KJ, Hak E, Goudsward WL, Schellevis FG, Hoepelman AIM, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. (2005) 41:281–8. doi: 10.1086/431587
2. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care. (2001) 24:1044–9. doi: 10.2337/diacare.24.6.1044
3. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. (2003) 26:510–3. doi: 10.2337/diacare.26.2.510
22. Endo Y, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes mellitus: management and relationship to glycemic control. Diabetes Metab Res Rev. (2007) 23:3–13. doi: 10.1002/dmrr.682
23. Matsushita M. Ficolins: complement-activating lectins involved in innate immunity. J Innate Immun. (2009) 2:24–32. doi: 10.1159/000228160
24. Endo Y, Iwaki D, Ishida Y, Takahashi M, Matsuhashita M, Fujita T. Mouse ficolin B has an ability to form complexes with mannose-binding lectin-associated serine proteases and activate complement through the lectin pathway. J Biomed Biotechnol. (2012) 2012:1–7. doi: 10.1155/2012/105891
25. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today. (1996) 17:532–40. doi: 10.1016/S0167-5699(96)80908-X
26. Ren Y, Ding Q, Zhang X. Ficolins and infectious diseases. Virol Sin. (2014) 29:25–32. doi: 10.1007/s12250-014-3421-2
27. Kilpatrick DC, Chalmers JD. Human L-ficolin (ficolin-2) and its clinical significance. J Biomed Biotechnol. (2012) 2012:1–10. doi: 10.1155/2012/138797
28. Ma YJ, Lee BL, Garred P. An overview of the synergy and crosstalk between pentraxins and collectins/ficolins: their functional relevance in complement activation. Exp Mol Med. (2017) 49:e320. doi: 10.1038/emmm.2017.51
29. Munthe-Fog L, Hummelshøj T, Honoré C, Madsen HO, Permin H, Garred P. Immunodeficiency associated with FCN1 mutation and ficolin-3 deficiency. N Engl J Med. (2009) 360:2637–44. doi: 10.1056/NEJMoa0900381
30. Schlabach LJ, Thiel S, Kessler U, Ammann RA, Aebi C, Jensenius JC. Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut. (2011) 60:1438–9. doi: 10.1136/gut.2010.226027
31. Sahagún-Ruiz A, Breda LCD, Castiblanco Valencia MM, Elias WP, Munthe-Fog L, Garred P, et al. Studies of the binding of ficolin-2 and ficolin-3 from the complement lectin pathway to Leptospira biflexa, Pasteurella pneumotropica and Diarrheagenic Escherichia coli. Immunobiology. (2015) 220:1177–85. doi: 10.1016/j.imbio.2015.06.001
32. Michalski M, Swierkó A, Łukasiewicz J, Man-Kupsińska A, Karwaciak I, Przygodzka P, et al. Ficolin-3 activity towards the opportunistic pathogen, Hafnia alvei. Immunobiology. (2015) 220:117–23. doi: 10.1016/j.imbio.2014.08.012
33. Alberti KGM, Zimet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: definition and diagnosis of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. (1998) 15:539–53. doi: 10.1002/smd.200041575-539; AID-DIA668-3.0.CO;2-S
34. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest. (1992) 101:1644–55.
35. Levy MM, Fink MP, Marshall JC, Abraham E, Angus DC, Cook D, et al. 2001 SCCM/ESICM/ACP/ATS/SIS international sepsis definitions conference. Crit Care Med. (2003) 31:1250–6. doi: 10.1097/01.CCM.0000050454.01978.3B
36. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjöholm AG, Wurzner R, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. (2005) 296:187–98. doi: 10.1016/j.jim.2004.11.016
37. Munthe-Fog L, Hummelshøj T, Honoré C, Madsen HO, Permin H, et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun. (2012) 13:515–22. doi: 10.1038/gene.2012.27
38. Munthe-Fog L, Hummelshøj T, Hansen BE, Koch C, Madsen HO, Skjødt M, et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol. (2007) 65:383–92. doi: 10.1111/j.1365-3083.2007.01915.x
39. Munthe-Fog L, Hummelshøj T, Ma YJ, Hansen BE, Koch C, Madsen HO, et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol. (2008) 44:2660–6. doi: 10.1016/j.molimm.2007.12.012
40. Garred P, Strom JJ, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. (2009) 198:1394–403. doi: 10.1086/579653
41. Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Aalderen NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetesologia. (2004) 47:1324–30. doi: 10.1007/s00125-004-1451-2
42. Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. (2017) 13:311–8. doi: 10.1038/nrneph.2017.31
43. Hair PS, Echague CG, Rohn RD, Krishna NK, Nyalwidhe JO, Cunnion KM. Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus. *J Transl Med.* (2012) 10:35. doi: 10.1186/1479-5876-10-35

44. Borné Y, Muhammad IF, Lorés-Motta L, Hedblad B, Nilsson PM, Melander Ö, et al. Complement C3 associates with incidence of diabetes, but no evidence of a causal relationship. *J Clin Endocrinol Metab.* (2017) 102:4477–85. doi: 10.1210/jc.2017-00948

45. Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, et al. A journey through the lectin pathway of complement—MBL and beyond. *Immunol Rev.* (2016) 274:74–97. doi: 10.1111/imr.12468

46. Pagowska-Klimek I, Cedzynski M. Mannan-binding lectin in cardiovascular disease. *Biomed Res Int.* (2014) 2014:1–13. doi: 10.1155/2014/616817

47. Sallenbach S, Thiel S, Aebi C, Otth M, Bigler S, Jensenius JC, et al. Serum concentrations of lectin-pathway components in healthy neonates, children and adults: Mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). *Pediatr Allergy Immunol.* (2011) 22:424–30. doi: 10.1111/j.1399-3038.2010.01104.x

48. Schlabach IJ, Aebi C, Hansen AG, Hirt A, Jensenius JC, Ammann RA. H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. *Clin Exp Immunol.* (2009) 157:83–89. doi: 10.1111/j.1365-2249.2009.03957.x

49. İslak Mutcalı S, Saltoglu N, Balkan II, Özaras R, Yemişen M, Tabak F, et al. Early Changes of mannose-binding lectin, H-ficolin, and procalcitonin in patients with febrile neutropenia: a prospective observational study. *Turkish J Haematol Off J Turkish Soc Haematol.* (2016) 33:304–10. doi: 10.4274/ijh.2014.0385

50. Hansen MB, Rasmussen LS, Pilely K, Hellemann D, Hein E, Madsen MB, et al. The lectin complement pathway in patients with necrotizing soft tissue infection. *J Innate Immun.* (2016) 8:507–16. doi: 10.1159/000447327

51. Csuka D, Munthe-Fog L, Skjoedt MO, Kocsis A, Zotter Z, Gál Pet al. The role of ficolins and MASPs in hereditary angioedema due to C1-inhibitor deficiency. *Mol Immunol.* (2015) 54:271–7. doi: 10.1016/j.molimm.2012.12.015

52. Prohászka Z, Munthe-Fog L, Ueland T, Gombos T, Yndestad A, Förhécz Z, et al. Association of ficolin-3 with severity and outcome of chronic heart failure. *PLoS ONE.* (2013) 8:e60976. doi: 10.1371/journal.pone.0060976

53. Hummelshøj T, Fog LM, Madsen HO, Sim RB, Garred P. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). *Mol Immunol.* (2008) 45:1623–32. doi: 10.1016/j.molimm.2007.10.006

54. Tsujimura M, Miyazaki T, Kojima E, Sagara Y, Shiraki H, Okochi K, et al. Serum concentration of Hakata antigen, a member of the ficolins, is linked with inhibition of *Aerococcus viridans* growth. *Clin Chim Acta.* (2002) 325:139–46. doi: 10.1016/S0009-8981(02)00274-7

55. Sørensen CA, Rosbjerg A, Jensen BH, Kroghelt KA, Garred P. The lectin complement pathway is involved in protection against enteraggregative *Escherichia coli* infection. *Front Immunol.* (2018) 9:1153. doi: 10.3389/fimmu.2018.01153

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer AS and handling Editor declared their shared affiliation.

Copyright © 2019 Barkai, Sipter, Csuka, Prohászka, Pilely, Garred and Hosszúfalusi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.